Do you want to read an article? Please log in or register.
Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device
Therapy and Intervention
Related content
Heart, Artery and Coronary DiseasesTherapy and Intervention
Comparison of a Pure Plug-Based versus a Primary Suture-Based Vascular Closure Device Strategy for Transfemoral Transcatheter Aortic Valve Replacement: The CHOICE-CLOSURE Randomized Clinical Trial
Circulation
Abdel-Wahab M, Hartung P, Dumpies O, Obradovic D, Wilde J, Majunke N, Boekstegers P, Müller R, Seyfarth M, Vorpahl M, Kiefer P, Noack T, Leontyev S, Sandri M, Rotta Detto Loria J, Kitamura M, Borger MA, Funkat AK, Hohenstein S, Desch S, Desch S, Holzhey D, Thiele H, CHOICE-CLOSURE Investigators.
doi: 10.1161/CIRCULATIONAHA.121.057856
Thrombosis and Stroke
Primary Outcome Evaluation of a Next Generation Left Atrial Appendage Closure Device: Results from the PINNACLE FLX Trial
Circulation
Kar S, Doshi SK, Sadhu A, Horton R, Osorio J, Ellis C, Stone J Jr, Shah M, Dukkipati SR, Adler S, Nair DG, Kim J, Wazni O, Price MJ, Asch FM, Holmes DR Jr, Shipley RD, Gordon NT, Allocco DJ, Reddy VY, PINNACLE FLX Investigators.
doi: 10.1161/CIRCULATIONAHA.120.050117
Atrial FibrillationThrombosis and StrokeTherapy and Intervention
Incidence, Characteristics, and Clinical Course of Device-Related Thrombus After Watchman Left Atrial Appendage Occlusion Device Implantation in Atrial Fibrillation Patients
JACC: Clinical Electrophysiology.
Kubo S, Mizutani Y, Meemook K, Nakajima Y, Hussaini A, Kar S
doi: 10.1016/j.jacep.2017.05.006.
Myocardial InfarctionThrombosis and StrokeTherapy and Intervention
Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings from the EXTEND-DAPT Study
Circulation
Butala NM, Faridi KF, Tamez H, Strom JB, Song Y, Shen C, Secemsky EA, Mauri L, Kereiakes DJ, Curtis JP, Gibson CM, Yeh RW
doi: 10.1161/CIRCULATIONAHA.121.056878
Cardiac Arrest or Death
Safety of mechanical chest compression devices AutoPulse and LUCAS in cardiac arrest: a randomized clinical trial for non-inferiority
European Heart Journal.
Koster RW, Beenen LF, van der Boom EB, Spijkerboer AM, Tepaske R, van der Wal AC, Beesems SG, Tijssen JG
doi: 10.1093/eurheartj/ehx318.
COMMENTED
Cardiovascular Risk and Diseases
Effectiveness and safety of empagliflozin in routine care patients: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Obes Metab
Elisabetta PE, Pawar A, Wexler D, Glynn RJ, Bessette LG, Paik JM, Najafzadeh M, Brodovicz KG, Déruaz-Luyet A, Schneeweiss S
doi: 10.1111/dom.14593
Heart Failure
One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial
JAMA Cardiol.
Shah SJ, Feldman T, Ricciardi MJ, Kahwash R, Lilly S, Litwin S, Nielsen CD, van der Harst P, Hoendermis E, Penicka M, Bartunek J, Fail PS, Kaye DM, Walton A, Petrie MC, Walker N, Basuray A, Yakubov S, Hummel SL, Chetcuti S, Forde-McLean R, Herrmann HC, Burkhoff D, Massaro JM, Cleland JGF, Mauri L
doi: 10.1001/
Atrial Fibrillation
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
BMJ.
Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB
doi: 10.1136/bmj.j510.
Atrial FibrillationTherapy and Intervention
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial
Circ Cardiovasc Interv.
Berry NC, Mauri L, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP
doi: 10.1161/CIRCINTERVENTIONS.119.008349.